Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

Grebely, Jason;Mauss, Stefan;Brown, Ashley;Bronowicki, Jean-Pierre;Puoti, Massimo;Wyles, David;Natha, Macky;Zhu, Yanni;Yang, Junming;Kreter, Bruce;Brainard, Diana M.;Yun, Chohee;Carr, Val;Dore, Gregory J.;
clinical infectious diseases 2016 Vol. 63 pp. 1405-1411
181
jason2016clinicalefficacy

Abstract

In this post-hoc analysis of the phase 3 ION trials evaluating hepatitis C virus therapy with ledipasvir/sofosbuvir ± ribavirin, current opioid substitution the

Keywords

Access

URL:
https://academic.oup.com/cid/article/63/11/1405/25...

Citation

ID: 267601
Ref Key: jason2016clinicalefficacy
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
267601
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store